Mirae Asset Global Investments Co. Ltd. Decreases Position in Natera, Inc. (NASDAQ:NTRA)

Mirae Asset Global Investments Co. Ltd. trimmed its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 51.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 86,199 shares of the medical research company’s stock after selling 90,960 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Natera were worth $5,400,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in NTRA. RiverPark Advisors LLC purchased a new position in shares of Natera during the fourth quarter valued at approximately $27,000. Harvest Fund Management Co. Ltd bought a new stake in Natera during the third quarter valued at approximately $44,000. CWM LLC grew its position in Natera by 224.4% during the third quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after buying an additional 911 shares during the period. Captrust Financial Advisors boosted its position in shares of Natera by 186.4% in the second quarter. Captrust Financial Advisors now owns 2,248 shares of the medical research company’s stock worth $80,000 after purchasing an additional 1,463 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Natera by 215.2% during the first quarter. PNC Financial Services Group Inc. now owns 2,049 shares of the medical research company’s stock worth $83,000 after acquiring an additional 1,399 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 1,958 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $68.16, for a total value of $133,457.28. Following the transaction, the chief executive officer now owns 175,550 shares in the company, valued at approximately $11,965,488. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Natera news, insider John Fesko sold 2,358 shares of the firm’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $65.09, for a total value of $153,482.22. Following the completion of the sale, the insider now directly owns 108,494 shares of the company’s stock, valued at approximately $7,061,874.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Steven Leonard Chapman sold 1,958 shares of the firm’s stock in a transaction on Monday, January 22nd. The stock was sold at an average price of $68.16, for a total value of $133,457.28. Following the completion of the sale, the chief executive officer now directly owns 175,550 shares of the company’s stock, valued at $11,965,488. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 366,477 shares of company stock worth $28,552,682. Corporate insiders own 9.42% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Raymond James cut shares of Natera from a “strong-buy” rating to an “outperform” rating and raised their price target for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Sanford C. Bernstein upgraded shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research note on Friday, April 5th. BTIG Research lifted their price objective on shares of Natera from $75.00 to $85.00 and gave the stock a “buy” rating in a research note on Friday, December 29th. Piper Sandler lifted their price target on Natera from $70.00 to $110.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 6th. Finally, Canaccord Genuity Group lifted their price objective on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. One research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. Based on data from MarketBeat, Natera presently has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Natera Trading Down 4.3 %

Shares of NASDAQ:NTRA opened at $90.42 on Tuesday. The business’s 50 day moving average price is $84.58 and its 200-day moving average price is $64.91. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The firm has a market capitalization of $10.92 billion, a price-to-earnings ratio of -23.86 and a beta of 1.37. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $98.82.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. The company had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. On average, equities research analysts forecast that Natera, Inc. will post -2.35 earnings per share for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.